I don't have an immediate SP when E4 FDA approval is announced.
My long term target is $2.00 per share on the basis no further capital is required and that E4 is a new drug protected by patent. I believe patent protection will be quite valuable and that will allow MYX and partner Mithra to grow US market share in a couple of years. That is my investment thesis for MYX notwithstanding that generics is a tough business and Scott Richards is a very poor CEO. Hopefully a new MYX Chairman will replace him with a US pharma industry leader.
MYX Price at posting:
32.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)